Skandinaviska Enskilda Banken Ab (Publ) Vaxcyte, Inc. Call Options Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $19.9 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PCVX
# of Institutions
344Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$397 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$392 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$383 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$323 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$209 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.93B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...